Featured Research

from universities, journals, and other organizations

HIV vaccine research must consider various immune responses

Date:
April 3, 2014
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
Future HIV vaccine research must consider both protective immune responses and those that might increase susceptibility to infection, a new article suggests. Between 2005 and 2013, investigational HIV vaccines based on recombinant adenovirus type 5 (rAd5), a weakened type of cold virus designed to deliver genetic material, were tested in three clinical trials. Two of those studies, known as Step and Phambili, involved the same experimental vaccine. Both studies showed no efficacy against acquisition of HIV infection; however, they suggested an increased risk of HIV acquisition among vaccinated male study participants.

Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility to HIV infection. In a new perspectives article appearing in the journal Science, HIV research leaders from NIAID (Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D.) and its grantees at Emory University (Eric Hunter, Ph.D.) and the University of California, San Francisco (Susan Buchbinder, M.D.), summarize the findings and considerations for future HIV vaccine research.

Between 2005 and 2013, investigational HIV vaccines based on recombinant adenovirus type 5 (rAd5), a weakened type of cold virus designed to deliver genetic material, were tested in three clinical trials. Two of those studies, known as Step and Phambili, involved the same experimental vaccine. Both studies showed no efficacy against acquisition of HIV infection; however, they suggested an increased risk of HIV acquisition among vaccinated male study participants. Based on subsequent analyses, the authors hypothesize that the rAd5-based vaccines tested may have heightened susceptibility to HIV infection by activating for sustained periods CD4+ T-cells, the key target for HIV, while producing ineffective or limited protective effects against HIV.

Given the lack of efficacy demonstrated by rAd-5 based HIV candidates and the potential increased risk for HIV acquisition, further development of HIV vaccines using rAd-5 vectors are inappropriate, the authors write. Researchers who want to pursue HIV vaccines using different adenoviruses or other vaccine delivery systems should perform a risk-benefit analysis that weighs the balance between the potential anti-HIV vaccine responses and protective benefit of the vaccine against the vaccine-induced risk of increased HIV acquisition due to heightened CD4+ T-cell activation. Moving forward, the HIV vaccine research field would benefit by clarifying the role vaccine vectors play in overall HIV vaccine effectiveness, identifying biomarkers in nonhuman primates that indicate increased risk for HIV acquisition, and developing a better understanding of mucosal immune system responses to HIV vaccination, according to the authors.


Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. S. Fauci, M. A. Marovich, C. W. Dieffenbach, E. Hunter, S. P. Buchbinder. Immune Activation with HIV Vaccines. Science, 2014; 344 (6179): 49 DOI: 10.1126/science.1250672

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "HIV vaccine research must consider various immune responses." ScienceDaily. ScienceDaily, 3 April 2014. <www.sciencedaily.com/releases/2014/04/140403142027.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2014, April 3). HIV vaccine research must consider various immune responses. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2014/04/140403142027.htm
NIH/National Institute of Allergy and Infectious Diseases. "HIV vaccine research must consider various immune responses." ScienceDaily. www.sciencedaily.com/releases/2014/04/140403142027.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins